Vanda Pharmaceuticals (VNDA) Other Non Operating Income (2023)

Vanda Pharmaceuticals (VNDA) reported Other Non Operating Income of $21000.0 for Q4 2023.

Vanda Pharmaceuticals (VNDA) Other Non Operating Income (2023) Analysis & Trends

Vanda Pharmaceuticals (VNDA) has 1 years of Other Non Operating Income data on file, last reported at $21000.0 in Q4 2023.

For the quarter ending Q4 2023, Other Non Operating Income changed N/A year-over-year to $21000.0; the trailing twelve-month figure through Dec 2023 stood at $21000.0 (changed N/A YoY), and the FY2023 full-year result was $21000.0, changed N/A from the prior year.
Other Non Operating Income steadied at $21000.0 in Q4 2023.
In the past five years, Other Non Operating Income ranged from a high of $21000.0 in Q4 2023 to a low of $21000.0 in Q4 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,140.12 Bn	66,139.83 Bn	-
2	Nanobiotix	1,912.79 Bn	1,912.73 Bn	-
3	Akari Therapeutics	1,022.34 Bn	1,022.34 Bn	-
4	BeOne Medicines	472.60 Bn	467.81 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.34 Bn	115.09 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.14 Bn	61.39 Bn	3.31 Bn
7	Belite Bio	62.79 Bn	62.79 Bn	-
8	Argenx Se	56.19 Bn	51.00 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.50 Bn	34.49 Bn	959.66 Mn
10	Vanda Pharmaceuticals	315.14 Mn	112.83 Mn	48.56 Mn

Historic Data

Download Data

Date	Value
Dec 31, 2023	21,000.00